Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 405

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Open access
Bachy, Emmanuel, Le Gouill, Steven, Di Blasi, Roberta, Sesques, Pierre, Manson, Guillaume, Cartron, Guillaume, Beauvais, David, Roulin, Louise, Gros, François Xavier, Rubio, Marie Thérèse, Bories, Pierre, Bay, Jacques Olivier, Llorente, Cristina Castilla, Choquet, Sylvain, Casasnovas, René-Olivier, Mohty, Mohamad, Guidez, Stéphanie, Joris, Magalie, Loschi, Michaël, Carras, Sylvain, Abraham, Julie, Chauchet, Adrien, Drieu La Rochelle, Laurianne, Deau-Fischer, Bénédicte, Hermine, Olivier, Gastinne, Thomas, Tudesq, Jean Jacques, Gat, Elodie, Broussais, Florence, Thieblemont, Catherine, Houot, Roch, Morschhauser, Franck·2022·Nature Medicine

Abstract

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel or tisa-cel and were registered in the retrospective French DESCAR-T registry study (NCT04328298). After 1:1 propensity score matching (n = 418), the best overall response rate/complete response rate (ORR/CRR) was 80%/60% versus 66%/42% for patients treated with axi-cel compared to tisa-cel, respectively (P < 0.001 for both ORR and CRR comparisons). After a median follow-up of 11.7 months, the 1-year progression-free survival was 46.6% for axi-cel and 33.2% for tisa-cel (hazard ratio (HR) = 0.61; 95% confidence interval (CI), 0.46–0.79; P = 0.0003). Overall survival (OS) was also significantly improved after axi-cel infusion compared to after tisa-cel infusion (1-year OS 63.5% versus 48.8%; HR = 0.63; 95% CI, 0.45–0.88; P = 0.0072). Similar findings were observed using the inverse probability of treatment weighting statistical approach. Grade 1–2 cytokine release syndrome was significantly more frequent with axi-cel than with tisa-cel, but no significant difference was observed for grade ≥3. Regarding immune effector cell-associated neurotoxicity syndrome (ICANS), both grade 1–2 and grade ≥3 ICANS were significantly more frequent with axi-cel than with tisa-cel. In conclusion, our matched comparison study supports a higher efficacy and also a higher toxicity of axi-cel compared to tisa-cel in the third or more treatment line for R/R DLBCL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01969-y

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 405

Metadata

Authors
Bachy, E., Le Gouill, S., Di Blasi, R., Sesques, P., Manson, G., Cartron, G., Beauvais, D., Roulin, L., Gros, F. X., Rubio, M. T., Bories, P., Bay, J. O., Llorente, C. C., Choquet, S., Casasnovas, R.-O., Mohty, M., Guidez, S., Joris, M., Loschi, M., Carras, S., Abraham, J., Chauchet, A., Drieu La Rochelle, L., Deau-Fischer, B., Hermine, O., Gastinne, T., Tudesq, J. J., Gat, E., Broussais, F., Thieblemont, C., Houot, R., & Morschhauser, F.
Venue
Nature Medicine
Published
2022-09-22
Volume
28
Issue
10
Pages
2145-2154
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4296685812
Cited by
405
References
35
FWCI
29.64
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. https://app.cochat.ai/papers/10.1038/s41591-022-01969-y
The paper
Bachy, E., Le Gouill, S., Di Blasi, R., Sesques, P., Manson, G., Cartron, G., Beauvais, D., Roulin, L., Gros, F. X., Rubio, M. T., Bories, P., Bay, J. O., Llorente, C. C., Choquet, S., Casasnovas, R.-O., Mohty, M., Guidez, S., Joris, M., Loschi, M., . . . Morschhauser, F. (2022). A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nature Medicine. https://doi.org/10.1038/s41591-022-01969-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.